Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have a confirmed diagnosis of relapsing remitting MS per the 2010 McDonald criteria.
Must have a known tetanus immunization history with most recent tetanus vaccination given 2 to 15 years prior to Screening and an anti-tetanus serum immunoglobulin titer at Screening that is less than or equal to one-half the upper limit of detection for the assay.
Must have been on a stable approved dose of Tecfidera (240 mg twice daily \[BID\]) \[Group 1\] for ≥6 months or on a stable approved dose of a non-pegylated IFN (e.g., Avonex, Betaseron, Rebif, Extavia) \[Group 2\] for ≥3 months prior to Day 1.
You may not be if
Clinical relapse requiring treatment within 30 days prior to Day 1.
Pneumococcal vaccination within 5 years prior to Screening.
Previous exposure to meningococcal vaccines.
Known hypersensitivity to Td, PPSV23, or MCV4 or their components.
Clareo Health | Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
